Additionally, combinatorial approaches using AXL inhibitors in conjunction with targeted agents against other dysregulated pathways in AML, such as FLT3 inhibitors or BCL-2 inhibitors, hold potential for overcoming therapeutic resistance. Here, AXL is linked to acute myeloid leukemia.